Quality of life in patients with psoriasis: the contribution of clinical variables and psoriasis-specific stress

BACKGROUND Psoriasis is a chronic inflammatory disease of the skin that affects patients of all ages andboth genders. The impact of the disease on quality of life is greater among patients with moderate to severe psoriasis. OBJECTIVE to establish a correlation between the psoriasis area and severity index (PASI) and theDermatology Life Quality Index (DLQI) based on a quality of life questionnaire adapted to the Brazilian contextfor patients with plaque psoriasis before and after systemic treatment. METHODSThis was a cross-sectional, descriptive study of psoriasis patients who did not undergo treatment or who manifested clinical activity of the disease. Patients were evaluated according to the PASI and the quality of life questionnaire adapted to theBrazilian context before and 60 days after systemic treatment. RESULTS Thirty-five patients participated in thestudy. Twenty-six were men, with a mean age of 46 years. There was no correlation between the PASI and thequality of life questionnaire adapted to the Brazilian context, but there was a correlation between the PASI andsome items of the quality of life questionnaire adapted to the Brazilian context, such as jobs involving public contact. CONCLUSIONThe non-correlation between the PASI and the quality of life questionnaire adapted to the Brazilian context in this work may be associated with a history of chronic disease, which implies greater acceptance of the illness, or may be related to the low income and social status of the patients studied. The correlationobserved among patients with careers involving public contact suggests that some professions are more impacted by the disease. It may be necessary to adapt the quality of life questionnaire to patients with a low income andcultural and social limitations. The small sample size (n=35 patients) and the short follow-up period of 60 dayswere some of the limitations of this work.

show abstract

“…10-14 Few studies in the literature show similar results and give support to those found in the present investigation. 15,16 …”

Section: Discussionmentioning

confidence: 99%

Psoriasis: correlation between severity index (PASI) and systemic treatment

Silva

Fortes

Miot

et al. 2013

An. Bras. Dermatol.

View full text Add to dashboard Cite

show abstract

“…Psoriasis influences significantly the health-related quality of life (HRQoL) issues, including the physical, psychological and social facets of the patient’s life 56,57. For this reason, as proved by different studies, the treatment with infliximab is effective even on patient QoL.…”

Section: Infliximab Quality Of Life and Nail Involvementmentioning

confidence: 99%

Infliximab in the treatment of plaque type psoriasis

Saraceno

Saggini²,

Pietroleonardo³

et al. 2009

CCID

View full text Add to dashboard Cite

Psoriasis is a chronic and immunomediated skin disease characterized by erythematous scaly plaques. Psoriasis affects approximately 1% to 3% of the Caucasian population. Tumor necrosis factor alpha (TNF-α) is a proinflammatory cytokine that plays a critical role in the pathogenesis of psoriasis. Infliximab is an anti-TNF-α drug widely used for the treatment of plaque type psoriasis and psoriatic arthritis. Controlled clinical trials demonstrated that infliximab is characterized by a high degree of clinical response in moderate to severe plaque psoriasis. Moreover infliximab showed rapid efficacy in nail psoriasis which represents a therapeutic challenge for dermatologists and a relevant source of distress for patients with plaque psoriasis. This anti-TNF-α has an encouraging safety profile, especially as long as physicians are watchful in prevention and early diagnosis of infections and infuse reactions. The efficacy, tolerability and safety profiles suggest infliximab as a suitable anti-psoriatic drug in the long-term treatment of a chronic disease such as plaque-type psoriasis.

show abstract

“…In studies directed to treatment of special sensitive skin areas modified PASI or target area scores (TAS) were employed. Some studies included an evaluation of patients’ quality of life during treatment using the psoriasis disability index (PDI) or quality of life (QOL) questionnaires about daily activities 31,32…”

Section: Clinical Studies – General Methodologymentioning

confidence: 99%

Novel topical therapy for mild-to-moderate plaque psoriasis: focus on calcitriol

Kowalzick

2009

CCID

View full text Add to dashboard Cite

The benefits of vitamin D derivatives for the treatment of chronic plaque psoriasis are well documented. Of importance is how compatible they are with, and how they compare to, other established treatments for psoriasis. This paper reviews 15 studies with calcitriol 3 μg g−1 ointment (Silkis®/Vectical™ ointment; Galderma Laboratories) applied twice daily for up to 52 weeks. The ointment was found to be effective and safe for the treatment of mild-to-moderate plaque psoriasis including sensitive skin areas. Calcitriol 3 μg g−1 ointment was found to be as effective as, or even superior to, other established treatment modalities and more highly tolerated than other local treatment modalities in most studies’ comparisons. It could be combined with other psoriasis treatment modalities such as ultraviolet B phototherapy or topical corticosteroids in order to achieve a faster response and in order to reduce the risk of adverse events.

show abstract

Quality of life in patients with psoriasis: the contribution of clinical variables and psoriasis-specific stress

Cited by 167 publications

References 17 publications

Psoriasis: correlation between severity index (PASI) and systemic treatment

Psoriasis: correlation between severity index (PASI) and systemic treatment

Infliximab in the treatment of plaque type psoriasis

Novel topical therapy for mild-to-moderate plaque psoriasis: focus on calcitriol

Contact Info

Product

Resources

About